Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response

Karthik Ramasamy, Ross Sadler, Sally Jeans, Paul Weeden, Sherin Varghese, Alison Turner, Jemma Larham, Nathanael Gray, Oluremi Carty, Joe Barrett, Stella Bowcock, Udo Oppermann, Gordon Cook, Chara Kyriakou, Mark Drayson, Supratik Basu, Sally Moore, Sarah McDonald, Sarah Gooding, Muhammad K Javaid
doi: https://doi.org/10.1101/2021.10.21.21265158

Article Information

doi 
https://doi.org/10.1101/2021.10.21.21265158
History 
  • October 25, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Karthik Ramasamy, MBBS1,*,
  2. Ross Sadler, PhD2,
  3. Sally Jeans3,
  4. Paul Weeden3,
  5. Sherin Varghese, MSc4,
  6. Alison Turner5,
  7. Jemma Larham, MSc6,
  8. Nathanael Gray5,
  9. Oluremi Carty, BSc2,
  10. Joe Barrett5,
  11. Stella Bowcock, MBBS7,
  12. Udo Oppermann, PhD5,
  13. Gordon Cook, PhD8,
  14. Chara Kyriakou, PhD9,
  15. Mark Drayson, PhD10,
  16. Supratik Basu, MBBS11,
  17. Sally Moore, MD12,
  18. Sarah McDonald, MSc13,
  19. Sarah Gooding, MBBCh14,15 and
  20. Muhammad K Javaid, MBBS5
  1. 1Oxford University Hospitals NHS Trust, Radcliffe department of Medicine, Oxford University, Oxford, UK
  2. 2Department of Immunology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  3. 3The Botnar Research Centre, Windmill Road, Headington, UK
  4. 4Late Phase Haematology, Oxford University Hospital NHS Foundation Trust, Churchill Hospital, Churchill Drive, Oxford, UK
  5. 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  6. 6Oxford University Hospitals NHS Trust, Oxford, UK
  7. 7Princess Royal University Hospital, King’s College Hospital Foundation NHS Trust, Farnborough Common, Orpington, Kent, UK
  8. 8NIHR Leeds Medtech & In vitro Diagnostics Cooperative, Leeds Teaching Hospitals Trust, UK
  9. 9Department of Haematology, University College London Hospitals NHS Trust, London, UK
  10. 10College of Medical and Dental Sciences Medical School, University of Birmingham, Edgbaston, Birmingham, UK
  11. 11University of Wolverhampton, The Royal Wolverhampton NHS Trust, UK
  12. 12Oxford University Hospitals NHS Trust NHS Foundation Trust, Oxford and Bath Royal United Hospitals, Bath, UK
  13. 13Myeloma UK, Beaverbank Business Park, Edinburgh
  14. 14MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
  15. 15Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK
  1. ↵*Corresponding Author:
    Karthik Ramasamy MBBS, FRCP, FRCPath, PhD, Oxford University Hospitals NHS Trust & Oxford University, Email : karthik.ramasamy{at}ndcls.ox.ac.uk, Tel: +441865235882
Back to top
Posted October 25, 2021.
Download PDF
Data/Code
Email
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response
Karthik Ramasamy, Ross Sadler, Sally Jeans, Paul Weeden, Sherin Varghese, Alison Turner, Jemma Larham, Nathanael Gray, Oluremi Carty, Joe Barrett, Stella Bowcock, Udo Oppermann, Gordon Cook, Chara Kyriakou, Mark Drayson, Supratik Basu, Sally Moore, Sarah McDonald, Sarah Gooding, Muhammad K Javaid
medRxiv 2021.10.21.21265158; doi: https://doi.org/10.1101/2021.10.21.21265158
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area